New era in nasopharyngeal cancer: Toripalimab opens doors for immunotherapy.
For decades, nasopharyngeal cancer patients facing recurrent or metastatic disease had limited treatment options.
top of page
4 min read
Hope on the horizon: TAK-500 takes aim at nasopharyngeal cancer.
Nasopharyngeal cancer (NPC) is a rare form of cancer that originates in the upper part of the throat behind the nose, known as the nasophary
23 views
3 min read
Deferred surgery for kidney cancer: A viable option in the age of improved systemic therapies?
Newer targeted therapies and immunotherapies approved over the last decade can effectively manage metastatic kidney cancer on their own.
6 views
4 min read
Immunotherapy triumphs in kidney cancer: A comparative look
Kidney cancer is a type of cancer that occurs when the cells in the kidney multiply rapidly and uncontrollably.
17 views
4 min read
Antibody-drug conjugates in the treatment of uterine cancers: A promising therapeutic approach
Uterine cancers, which largely comprise endometrial cancer and uterine sarcoma, are a considerable health concern affecting women worldwide.
10 views
4 min read
Can olutasidenib help in acute myeloid leukemia treatment?
Acute myeloid leukemia (AML) is a malignancy of the blood and bone marrow.
8 views
3 min read
Is durvalumab a breakthrough treatment for gallbladder cancer?
Gallbladder cancer (GBC) is one of the most prevalent among biliary tract duct cancers globally.
14 views
3 min read
Neoantigen vaccine for the treatment of liver cancer: a paradigm-shifting opportunity
One of the most promising and rapidly expanding fields of cancer research and treatment is cancer immunotherapy.
5 views
4 min read
Is avelumab hold the promise of being a breakthrough treatment for gastric cancer?
Gastric cancer develops in the lining of the stomach and is one of the most common gastrointestinal malignancies, worldwide.
18 views
4 min read
Neoadjuvant nivolumab plus chemotherapy: Examining the clinical trial that led to FDA approval
Immunotherapy is transforming cancer treatment. One such immunotherapy drug called, nivolumab has been approved by FDA for lung cancer.
16 views
4 min read
Immunotherapy for the treatment of diffuse intrinsic pontine glioma: a paradigm-shift in opportunity
Brainstem glioma is a heterogeneous group of tumors that comprise diffuse intrinsic pontine glioma (DIPG), glioblastoma, etc.
4 views
Collaborators
Get new content delivered directly to your inbox.
bottom of page